The Impact of non-COVID-19 Infections to COVID-19 Disease in Hematological and Solid Organ Malignancies

Introduction:The aim of this study is to evaluate the clinical differences of COVID-19 infection in hematological and solid organ malignancy patients.Methods: In the study, patients who have followed up in the Necmettin Erbakan University Meram Medical Faculty Clinic of COVID-19 with a diagnosis of malignancy between 01 September 2020 and 01 January 2021 were compared in terms of epidemiological and clinical characteristics. Results:The study included 134 patients.Hospitalization day, intensive care need, convalescent plasma need, sedimentation and ferritin levels of patients diagnosed with hematological malignancies were significantly higher (p: 0.001, 0.008, 0.001, 0.001, <0.001 respectively), and the neutrophil, lymphocyte, platelet, and neutrophil-lymphocyte ratio was found to be low, according to the findings of the study.The cure rate of COVID infection was significantly lower with additionally infection in hematological malignancies (OR: 3.1, 95%; CI: 1.4-6.9;p: 0.004).In multivariate analysis, it was determined that an presence of non-COVID-19 infection increased the risk of death 2.8 times (95% CI; 1.3-6.5, p: 0.010).Discussion and Conclusion: Patients with hematological malignancy have experienced a more severe clinical course of COVID-19 and higher mortality than those with solid tumors.The use of a model in the COVID-19 pandemic that summarizes these non-COVID-19 infections, hematological parameters, age, and comorbidities can help in the method of malignant patients with high mortality risk.